Generate Biomedicines, Inc. (GENB)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in USD.

Revenue Quarterly

0 3.5M 7M 10.5M Q1 '25: 8.8M Q2 '25: 10.1M Q1 '26: 7.2M Q2 '26: 6.3M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q1 '25: -48.2M Q2 '25: -60.1M Q1 '26: -64.1M Q2 '26: -71.6M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Net Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q1 '25: -41.7M Q2 '25: -52.4M Q1 '26: -61.4M Q2 '26: -67.3M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-90M -60M -30M 0 30M 60M 90M Q1 '25: -53.2M Q2 '25: -48.8M Q1 '26: -80.4M Q2 '26: -57.9M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Free Cash Flow Quarterly

-90M -60M -30M 0 30M 60M 90M Q1 '25: -53.9M Q2 '25: -48.9M Q1 '26: -84.2M Q2 '26: -58.9M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q1 '25: 32.8M Q2 '25: 33M Q1 '26: 64.9M Q2 '26: 128.2M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.